8944829

Source:http://linkedlifedata.com/resource/pubmed/id/8944829

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003009, umls-concept:C0016536, umls-concept:C0042397, umls-concept:C0126174, umls-concept:C0598051, umls-concept:C0871261, umls-concept:C1280500, umls-concept:C1704632, umls-concept:C1706817, umls-concept:C1708335, umls-concept:C2911692
pubmed:issue	5
pubmed:dateCreated	1996-12-23
pubmed:abstractText	The angiotensin type 1 (AT1) receptor antagonist, losartan (orally administered), decreases vasoconstrictor effects of angiotensin II (Ang II). Oral losartan is converted into the active metabolite, Exp3174, which causes most of the antagonistic effects. Effects of losartan as such have not been studied after its intra-arterial administration in humans. Therefore, we investigated the effects of both intra-arterially and orally administered losartan on AT1-receptor-mediated vasoconstriction.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/8944829
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0077427
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II, http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents, http://linkedlifedata.com/resource/pubmed/chemical/Biphenyl Compounds, http://linkedlifedata.com/resource/pubmed/chemical/EXP3174, http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles, http://linkedlifedata.com/resource/pubmed/chemical/Losartan, http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles, http://linkedlifedata.com/resource/pubmed/chemical/Vasoconstrictor Agents
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0008-6363
pubmed:author	pubmed-author:BergA UAU, pubmed-author:ChangP CPC, pubmed-author:PfaffendorfMM, pubmed-author:VermeijPP, pubmed-author:van ZwietenP APA
pubmed:issnType	Print
pubmed:volume	32
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	973-9
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:8944829-Administration, Oral, pubmed-meshheading:8944829-Adult, pubmed-meshheading:8944829-Angiotensin II, pubmed-meshheading:8944829-Angiotensin Receptor Antagonists, pubmed-meshheading:8944829-Antihypertensive Agents, pubmed-meshheading:8944829-Biphenyl Compounds, pubmed-meshheading:8944829-Depression, Chemical, pubmed-meshheading:8944829-Dose-Response Relationship, Drug, pubmed-meshheading:8944829-Forearm, pubmed-meshheading:8944829-Humans, pubmed-meshheading:8944829-Imidazoles, pubmed-meshheading:8944829-Infusions, Intra-Arterial, pubmed-meshheading:8944829-Losartan, pubmed-meshheading:8944829-Male, pubmed-meshheading:8944829-Plethysmography, pubmed-meshheading:8944829-Tetrazoles, pubmed-meshheading:8944829-Vascular Resistance, pubmed-meshheading:8944829-Vasoconstrictor Agents
pubmed:year	1996
pubmed:articleTitle	Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed of healthy volunteers.
pubmed:affiliation	Department of Pharmacotherapy, University of Amsterdam, The Netherlands.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial